A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01843790

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
La Jolla Pharmaceutical Company (from the registry)
Registry
  • NCT NCT01843790
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01843790. Randomized; single masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
Intervention (Drug)
GCS-100
Intervention (Drug)
Placebo, Saline
Lead sponsor
La Jolla Pharmaceutical Company (class: industry)

Record details

Record id
cardio:ct-nct01843790
Content hash
836780159c7bb9c2f3cc3b655e994ac090a12658dc702ee4b9e9c25af87cdf61